APO Research
Talk to an analyst

APO RESEARCH · REPORT

Formulation Development CDMO

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Formulation Development CDMO Market Analysis and Forecast 2026-2032

5 June 2026242 pages

Choose your research edition.

Industry ResearchFormulation Development CDMO Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Formulation Development CDMO Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Formulation Development CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Formulation Development CDMO Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Formulation Development CDMO Market Analysis and Forecast 2026-2032242 pages · $4,950 USD

Market perspective

The global Formulation Development CDMO market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Formulation Development CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Formulation Development CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Formulation Development CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Formulation Development CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Formulation Development CDMO include Lonza, Ascendia Pharmaceutical Solutions, Catalent, Cambrex, Serán Bioscience, Singota Solutions, Adragos Pharma, Meribel Pharma and Eurofins CDMO, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Formulation Development CDMO, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Formulation Development CDMO, also provides the revenue of main regions and countries. Of the upcoming market potential for Formulation Development CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Formulation Development CDMO revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Formulation Development CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Formulation Development CDMO revenue, projected growth trends, production technology, application and end-user industry.

Formulation Development CDMO Segment by Company

Lonza

Ascendia Pharmaceutical Solutions

Catalent

Cambrex

Serán Bioscience

Singota Solutions

Adragos Pharma

Meribel Pharma

Eurofins CDMO

Skyepharma

Siegfried Group

Recipharm

CordenPharma

Thermo Fisher Scientific

Samsung Biologics

AGC Biologics

WuXi AppTec

Pharmaron

Asymchem

Huahai Pharma

Nipro Pharma

CMIC Group

Hovione

Formulation Development CDMO Segment by Type

Oral Solid Dosage Forms

Injectable Dosage Forms

Transdermal Dosage Forms

Others

Formulation Development CDMO Segment by Application

Small molecule chemical drugs

Biologics

Cell and gene therapy products

Others

Formulation Development CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Formulation Development CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Formulation Development CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Formulation Development CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Formulation Development CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Formulation Development CDMO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Formulation Development CDMO revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Formulation Development CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oral Solid Dosage Forms Major Player Table 3. Injectable Dosage Forms Major Player Table 4. Transdermal Dosage Forms Major Player Table 5. Others Major Player Table 6. Global Formulation Development CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Small molecule chemical drugs Major Player Table 8. Biologics Major Player Table 9. Cell and gene therapy products Major Player Table 10. Others Major Player Table 11. Formulation Development CDMO Industry Trends Table 12. Formulation Development CDMO Industry Drivers Table 13. Formulation Development CDMO Industry Opportunities and Challenges Table 14. Formulation Development CDMO Industry Restraints Table 15. Global Formulation Development CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Formulation Development CDMO Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Formulation Development CDMO Market Share by Region (2021-2026) Table 18. Global Formulation Development CDMO Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Formulation Development CDMO Market Share by Region (2027-2032) Table 20. Global Formulation Development CDMO Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Formulation Development CDMO Revenue Market Share by Players (2021-2026) Table 22. Global Formulation Development CDMO Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Formulation Development CDMO Key Players Headquarters & Area Served Table 24. Global Formulation Development CDMO Players, Product Type & Application Table 25. Global Formulation Development CDMO Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Formulation Development CDMO by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Formulation Development CDMO Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Formulation Development CDMO Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Formulation Development CDMO Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Formulation Development CDMO Revenue Market Share by Type (2021-2026) Table 32. Global Formulation Development CDMO Revenue Market Share by Type (2027-2032) Table 33. Global Formulation Development CDMO Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Formulation Development CDMO Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Formulation Development CDMO Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Formulation Development CDMO Revenue Market Share by Application (2021-2026) Table 37. Global Formulation Development CDMO Revenue Market Share by Application (2027-2032) Table 38. Lonza Company Information Table 39. Lonza Business Overview Table 40. Lonza Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Lonza Formulation Development CDMO Product Portfolio Table 42. Lonza Recent Development Table 43. Ascendia Pharmaceutical Solutions Company Information Table 44. Ascendia Pharmaceutical Solutions Business Overview Table 45. Ascendia Pharmaceutical Solutions Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Ascendia Pharmaceutical Solutions Formulation Development CDMO Product Portfolio Table 47. Ascendia Pharmaceutical Solutions Recent Development Table 48. Catalent Company Information Table 49. Catalent Business Overview Table 50. Catalent Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Catalent Formulation Development CDMO Product Portfolio Table 52. Catalent Recent Development Table 53. Cambrex Company Information Table 54. Cambrex Business Overview Table 55. Cambrex Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Cambrex Formulation Development CDMO Product Portfolio Table 57. Cambrex Recent Development Table 58. Serán Bioscience Company Information Table 59. Serán Bioscience Business Overview Table 60. Serán Bioscience Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Serán Bioscience Formulation Development CDMO Product Portfolio Table 62. Serán Bioscience Recent Development Table 63. Singota Solutions Company Information Table 64. Singota Solutions Business Overview Table 65. Singota Solutions Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Singota Solutions Formulation Development CDMO Product Portfolio Table 67. Singota Solutions Recent Development Table 68. Adragos Pharma Company Information Table 69. Adragos Pharma Business Overview Table 70. Adragos Pharma Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Adragos Pharma Formulation Development CDMO Product Portfolio Table 72. Adragos Pharma Recent Development Table 73. Meribel Pharma Company Information Table 74. Meribel Pharma Business Overview Table 75. Meribel Pharma Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Meribel Pharma Formulation Development CDMO Product Portfolio Table 77. Meribel Pharma Recent Development Table 78. Eurofins CDMO Company Information Table 79. Eurofins CDMO Business Overview Table 80. Eurofins CDMO Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Eurofins CDMO Formulation Development CDMO Product Portfolio Table 82. Eurofins CDMO Recent Development Table 83. Skyepharma Company Information Table 84. Skyepharma Business Overview Table 85. Skyepharma Formulation Development CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Skyepharma Formulation Development CDMO Product Portfolio Table 87. Skyepharma Recent Development Table 88. Siegfried Group Company Information Table 89. Siegfried Group Business Overview Table 90. Siegfried Group Formulation Development CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Siegfried Group Formulation Development CDMO Product Portfolio Table 92. Siegfried Group Recent Development Table 93. Recipharm Company Information Table 94. Recipharm Business Overview Table 95. Recipharm Formulation Development CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Recipharm Formulation Development CDMO Product Portfolio Table 97. Recipharm Recent Development Table 98. CordenPharma Company Information Table 99. CordenPharma Business Overview Table 100. CordenPharma Formulation Development CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. CordenPharma Formulation Development CDMO Product Portfolio Table 102. CordenPharma Recent Development Table 103. Thermo Fisher Scientific Company Information Table 104. Thermo Fisher Scientific Business Overview Table 105. Thermo Fisher Scientific Formulation Development CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Thermo Fisher Scientific Formulation Development CDMO Product Portfolio Table 107. Thermo Fisher Scientific Recent Development Table 108. Samsung Biologics Company Information Table 109. Samsung Biologics Business Overview Table 110. Samsung Biologics Formulation Development CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Samsung Biologics Formulation Development CDMO Product Portfolio Table 112. Samsung Biologics Recent Development Table 113. AGC Biologics Company Information Table 114. AGC Biologics Business Overview Table 115. AGC Biologics Formulation Development CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. AGC Biologics Formulation Development CDMO Product Portfolio Table 117. AGC Biologics Recent Development Table 118. WuXi AppTec Company Information Table 119. WuXi AppTec Business Overview Table 120. WuXi AppTec Formulation Development CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. WuXi AppTec Formulation Development CDMO Product Portfolio Table 122. WuXi AppTec Recent Development Table 123. Pharmaron Company Information Table 124. Pharmaron Business Overview Table 125. Pharmaron Formulation Development CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. Pharmaron Formulation Development CDMO Product Portfolio Table 127. Pharmaron Recent Development Table 128. Asymchem Company Information Table 129. Asymchem Business Overview Table 130. Asymchem Formulation Development CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 131. Asymchem Formulation Development CDMO Product Portfolio Table 132. Asymchem Recent Development Table 133. Huahai Pharma Company Information Table 134. Huahai Pharma Business Overview Table 135. Huahai Pharma Formulation Development CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 136. Huahai Pharma Formulation Development CDMO Product Portfolio Table 137. Huahai Pharma Recent Development Table 138. Nipro Pharma Company Information Table 139. Nipro Pharma Business Overview Table 140. Nipro Pharma Formulation Development CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 141. Nipro Pharma Formulation Development CDMO Product Portfolio Table 142. Nipro Pharma Recent Development Table 143. CMIC Group Company Information Table 144. CMIC Group Business Overview Table 145. CMIC Group Formulation Development CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 146. CMIC Group Formulation Development CDMO Product Portfolio Table 147. CMIC Group Recent Development Table 148. Hovione Company Information Table 149. Hovione Business Overview Table 150. Hovione Formulation Development CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 151. Hovione Formulation Development CDMO Product Portfolio Table 152. Hovione Recent Development Table 153. North America Formulation Development CDMO Revenue by Type (2021-2026) & (US$ Million) Table 154. North America Formulation Development CDMO Revenue by Type (2027-2032) & (US$ Million) Table 155. North America Formulation Development CDMO Revenue by Application (2021-2026) & (US$ Million) Table 156. North America Formulation Development CDMO Revenue by Application (2027-2032) & (US$ Million) Table 157. North America Formulation Development CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 158. North America Formulation Development CDMO Revenue by Country (2021-2026) & (US$ Million) Table 159. North America Formulation Development CDMO Revenue by Country (US$ Million) & (2027-2032) Table 160. Europe Formulation Development CDMO Revenue by Type (2021-2026) & (US$ Million) Table 161. Europe Formulation Development CDMO Revenue by Type (2027-2032) & (US$ Million) Table 162. Europe Formulation Development CDMO Revenue by Application (2021-2026) & (US$ Million) Table 163. Europe Formulation Development CDMO Revenue by Application (2027-2032) & (US$ Million) Table 164. Europe Formulation Development CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 165. Europe Formulation Development CDMO Revenue by Country (2021-2026) & (US$ Million) Table 166. Europe Formulation Development CDMO Revenue by Country (US$ Million) & (2027-2032) Table 167. China Formulation Development CDMO Revenue by Type (2021-2026) & (US$ Million) Table 168. China Formulation Development CDMO Revenue by Type (2027-2032) & (US$ Million) Table 169. China Formulation Development CDMO Revenue by Application (2021-2026) & (US$ Million) Table 170. China Formulation Development CDMO Revenue by Application (2027-2032) & (US$ Million) Table 171. Asia Formulation Development CDMO Revenue by Type (2021-2026) & (US$ Million) Table 172. Asia Formulation Development CDMO Revenue by Type (2027-2032) & (US$ Million) Table 173. Asia Formulation Development CDMO Revenue by Application (2021-2026) & (US$ Million) Table 174. Asia Formulation Development CDMO Revenue by Application (2027-2032) & (US$ Million) Table 175. Asia Formulation Development CDMO Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 176. Asia Formulation Development CDMO Revenue by Region (US$ Million) & (2021-2026) Table 177. Asia Formulation Development CDMO Revenue by Region (US$ Million) & (2027-2032) Table 178. SAMEA Formulation Development CDMO Revenue by Type (2021-2026) & (US$ Million) Table 179. SAMEA Formulation Development CDMO Revenue by Type (2027-2032) & (US$ Million) Table 180. SAMEA Formulation Development CDMO Revenue by Application (2021-2026) & (US$ Million) Table 181. SAMEA Formulation Development CDMO Revenue by Application (2027-2032) & (US$ Million) Table 182. SAMEA Formulation Development CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 183. SAMEA Formulation Development CDMO Revenue by Country (2021-2026) & (US$ Million) Table 184. SAMEA Formulation Development CDMO Revenue by Country (US$ Million) & (2027-2032) Table 185. Research Programs/Design for This Report Table 186. Authors List of This Report Table 187. Secondary Sources Table 188. Primary Sources List of Figures Figure 1. Formulation Development CDMO Image Figure 2. Global Formulation Development CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Formulation Development CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oral Solid Dosage Forms Image Figure 5. Injectable Dosage Forms Image Figure 6. Transdermal Dosage Forms Image Figure 7. Others Image Figure 8. Global Formulation Development CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Formulation Development CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 10. Small molecule chemical drugs Image Figure 11. Biologics Image Figure 12. Cell and gene therapy products Image Figure 13. Others Image Figure 14. Global Formulation Development CDMO Market Size (US$ Million) & (2021-2032) Figure 15. Global Formulation Development CDMO Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Formulation Development CDMO Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Formulation Development CDMO Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Formulation Development CDMO Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Formulation Development CDMO Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Formulation Development CDMO Revenue Market Share by Type (2021-2032) Figure 22. Global Formulation Development CDMO Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Formulation Development CDMO Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Formulation Development CDMO Revenue Market Share by Application (2021-2032) Figure 25. North America Formulation Development CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Formulation Development CDMO Revenue Share by Type (2021-2032) Figure 27. North America Formulation Development CDMO Revenue Share by Application (2021-2032) Figure 28. North America Formulation Development CDMO Revenue Share by Country (2021-2032) Figure 29. United States Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Formulation Development CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Formulation Development CDMO Revenue Share by Type (2021-2032) Figure 34. Europe Formulation Development CDMO Revenue Share by Application (2021-2032) Figure 35. Europe Formulation Development CDMO Revenue Share by Country (2021-2032) Figure 36. Germany Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Formulation Development CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Formulation Development CDMO Revenue Share by Type (2021-2032) Figure 46. China Formulation Development CDMO Revenue Share by Application (2021-2032) Figure 47. Asia Formulation Development CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Formulation Development CDMO Revenue Share by Type (2021-2032) Figure 49. Asia Formulation Development CDMO Revenue Share by Application (2021-2032) Figure 50. Asia Formulation Development CDMO Revenue Share by Region (2021-2032) Figure 51. Japan Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Formulation Development CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Formulation Development CDMO Revenue Share by Type (2021-2032) Figure 59. SAMEA Formulation Development CDMO Revenue Share by Application (2021-2032) Figure 60. SAMEA Formulation Development CDMO Revenue Share by Country (2021-2032) Figure 61. Brazil Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Formulation Development CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Solid Dosage Forms
  • Injectable Dosage Forms
  • Transdermal Dosage Forms
  • Others
Applications
  • Small molecule chemical drugs
  • Biologics
  • Cell and gene therapy products
  • Others
Companies covered
  • Lonza
  • Ascendia Pharmaceutical Solutions
  • Catalent
  • Cambrex
  • Serán Bioscience
  • Singota Solutions
  • Adragos Pharma
  • Meribel Pharma
  • Eurofins CDMO
  • Skyepharma
  • Siegfried Group
  • Recipharm
  • CordenPharma
  • Thermo Fisher Scientific
  • Samsung Biologics
  • AGC Biologics
  • WuXi AppTec
  • Pharmaron
  • Asymchem
  • Huahai Pharma
  • Nipro Pharma
  • CMIC Group
  • Hovione

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Formulation Development CDMO Market by Type
  3. 1.2.1 Global Formulation Development CDMO Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oral Solid Dosage Forms
  5. 1.2.3 Injectable Dosage Forms
  6. 1.2.4 Transdermal Dosage Forms
  7. 1.2.5 Others
  8. 1.3 Formulation Development CDMO Market by Application
  9. 1.3.1 Global Formulation Development CDMO Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Small molecule chemical drugs
  11. 1.3.3 Biologics
  12. 1.3.4 Cell and gene therapy products
  13. 1.3.5 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Formulation Development CDMO Market Dynamics
  1. 2.1 Formulation Development CDMO Industry Trends
  2. 2.2 Formulation Development CDMO Industry Drivers
  3. 2.3 Formulation Development CDMO Industry Opportunities and Challenges
  4. 2.4 Formulation Development CDMO Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Formulation Development CDMO Market Perspective (2021-2032)
  2. 3.2 Global Formulation Development CDMO Growth Trends by Region
  3. 3.2.1 Global Formulation Development CDMO Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Formulation Development CDMO Market Size by Region (2021-2026)
  5. 3.2.3 Global Formulation Development CDMO Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Formulation Development CDMO Revenue by Players
  2. 4.1.1 Global Formulation Development CDMO Revenue by Players (2021-2026)
  3. 4.1.2 Global Formulation Development CDMO Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Formulation Development CDMO Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Formulation Development CDMO Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Formulation Development CDMO Key Players Headquarters & Area Served
  7. 4.4 Global Formulation Development CDMO Players, Product Type & Application
  8. 4.5 Global Formulation Development CDMO Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Formulation Development CDMO Market CR5 and HHI
  11. 4.6.3 2025 Formulation Development CDMO Tier 1, Tier 2, and Tier 3
5 Formulation Development CDMO Market Size by Type
  1. 5.1 Global Formulation Development CDMO Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Formulation Development CDMO Revenue by Type (2021-2032)
  3. 5.3 Global Formulation Development CDMO Revenue Market Share by Type (2021-2032)
6 Formulation Development CDMO Market Size by Application
  1. 6.1 Global Formulation Development CDMO Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Formulation Development CDMO Revenue by Application (2021-2032)
  3. 6.3 Global Formulation Development CDMO Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Lonza
  2. 7.1.1 Lonza Company Information
  3. 7.1.2 Lonza Business Overview
  4. 7.1.3 Lonza Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Lonza Formulation Development CDMO Product Portfolio
  6. 7.1.5 Lonza Recent Developments
  7. 7.2 Ascendia Pharmaceutical Solutions
  8. 7.2.1 Ascendia Pharmaceutical Solutions Company Information
  9. 7.2.2 Ascendia Pharmaceutical Solutions Business Overview
  10. 7.2.3 Ascendia Pharmaceutical Solutions Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Ascendia Pharmaceutical Solutions Formulation Development CDMO Product Portfolio
  12. 7.2.5 Ascendia Pharmaceutical Solutions Recent Developments
  13. 7.3 Catalent
  14. 7.3.1 Catalent Company Information
  15. 7.3.2 Catalent Business Overview
  16. 7.3.3 Catalent Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Catalent Formulation Development CDMO Product Portfolio
  18. 7.3.5 Catalent Recent Developments
  19. 7.4 Cambrex
  20. 7.4.1 Cambrex Company Information
  21. 7.4.2 Cambrex Business Overview
  22. 7.4.3 Cambrex Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Cambrex Formulation Development CDMO Product Portfolio
  24. 7.4.5 Cambrex Recent Developments
  25. 7.5 Serán Bioscience
  26. 7.5.1 Serán Bioscience Company Information
  27. 7.5.2 Serán Bioscience Business Overview
  28. 7.5.3 Serán Bioscience Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Serán Bioscience Formulation Development CDMO Product Portfolio
  30. 7.5.5 Serán Bioscience Recent Developments
  31. 7.6 Singota Solutions
  32. 7.6.1 Singota Solutions Company Information
  33. 7.6.2 Singota Solutions Business Overview
  34. 7.6.3 Singota Solutions Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Singota Solutions Formulation Development CDMO Product Portfolio
  36. 7.6.5 Singota Solutions Recent Developments
  37. 7.7 Adragos Pharma
  38. 7.7.1 Adragos Pharma Company Information
  39. 7.7.2 Adragos Pharma Business Overview
  40. 7.7.3 Adragos Pharma Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Adragos Pharma Formulation Development CDMO Product Portfolio
  42. 7.7.5 Adragos Pharma Recent Developments
  43. 7.8 Meribel Pharma
  44. 7.8.1 Meribel Pharma Company Information
  45. 7.8.2 Meribel Pharma Business Overview
  46. 7.8.3 Meribel Pharma Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Meribel Pharma Formulation Development CDMO Product Portfolio
  48. 7.8.5 Meribel Pharma Recent Developments
  49. 7.9 Eurofins CDMO
  50. 7.9.1 Eurofins CDMO Company Information
  51. 7.9.2 Eurofins CDMO Business Overview
  52. 7.9.3 Eurofins CDMO Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Eurofins CDMO Formulation Development CDMO Product Portfolio
  54. 7.9.5 Eurofins CDMO Recent Developments
  55. 7.10 Skyepharma
  56. 7.10.1 Skyepharma Company Information
  57. 7.10.2 Skyepharma Business Overview
  58. 7.10.3 Skyepharma Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Skyepharma Formulation Development CDMO Product Portfolio
  60. 7.10.5 Skyepharma Recent Developments
  61. 7.11 Siegfried Group
  62. 7.11.1 Siegfried Group Company Information
  63. 7.11.2 Siegfried Group Business Overview
  64. 7.11.3 Siegfried Group Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Siegfried Group Formulation Development CDMO Product Portfolio
  66. 7.11.5 Siegfried Group Recent Developments
  67. 7.12 Recipharm
  68. 7.12.1 Recipharm Company Information
  69. 7.12.2 Recipharm Business Overview
  70. 7.12.3 Recipharm Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Recipharm Formulation Development CDMO Product Portfolio
  72. 7.12.5 Recipharm Recent Developments
  73. 7.13 CordenPharma
  74. 7.13.1 CordenPharma Company Information
  75. 7.13.2 CordenPharma Business Overview
  76. 7.13.3 CordenPharma Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  77. 7.13.4 CordenPharma Formulation Development CDMO Product Portfolio
  78. 7.13.5 CordenPharma Recent Developments
  79. 7.14 Thermo Fisher Scientific
  80. 7.14.1 Thermo Fisher Scientific Company Information
  81. 7.14.2 Thermo Fisher Scientific Business Overview
  82. 7.14.3 Thermo Fisher Scientific Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Thermo Fisher Scientific Formulation Development CDMO Product Portfolio
  84. 7.14.5 Thermo Fisher Scientific Recent Developments
  85. 7.15 Samsung Biologics
  86. 7.15.1 Samsung Biologics Company Information
  87. 7.15.2 Samsung Biologics Business Overview
  88. 7.15.3 Samsung Biologics Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Samsung Biologics Formulation Development CDMO Product Portfolio
  90. 7.15.5 Samsung Biologics Recent Developments
  91. 7.16 AGC Biologics
  92. 7.16.1 AGC Biologics Company Information
  93. 7.16.2 AGC Biologics Business Overview
  94. 7.16.3 AGC Biologics Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  95. 7.16.4 AGC Biologics Formulation Development CDMO Product Portfolio
  96. 7.16.5 AGC Biologics Recent Developments
  97. 7.17 WuXi AppTec
  98. 7.17.1 WuXi AppTec Company Information
  99. 7.17.2 WuXi AppTec Business Overview
  100. 7.17.3 WuXi AppTec Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  101. 7.17.4 WuXi AppTec Formulation Development CDMO Product Portfolio
  102. 7.17.5 WuXi AppTec Recent Developments
  103. 7.18 Pharmaron
  104. 7.18.1 Pharmaron Company Information
  105. 7.18.2 Pharmaron Business Overview
  106. 7.18.3 Pharmaron Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Pharmaron Formulation Development CDMO Product Portfolio
  108. 7.18.5 Pharmaron Recent Developments
  109. 7.19 Asymchem
  110. 7.19.1 Asymchem Company Information
  111. 7.19.2 Asymchem Business Overview
  112. 7.19.3 Asymchem Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Asymchem Formulation Development CDMO Product Portfolio
  114. 7.19.5 Asymchem Recent Developments
  115. 7.20 Huahai Pharma
  116. 7.20.1 Huahai Pharma Company Information
  117. 7.20.2 Huahai Pharma Business Overview
  118. 7.20.3 Huahai Pharma Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Huahai Pharma Formulation Development CDMO Product Portfolio
  120. 7.20.5 Huahai Pharma Recent Developments
  121. 7.21 Nipro Pharma
  122. 7.21.1 Nipro Pharma Company Information
  123. 7.21.2 Nipro Pharma Business Overview
  124. 7.21.3 Nipro Pharma Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Nipro Pharma Formulation Development CDMO Product Portfolio
  126. 7.21.5 Nipro Pharma Recent Developments
  127. 7.22 CMIC Group
  128. 7.22.1 CMIC Group Company Information
  129. 7.22.2 CMIC Group Business Overview
  130. 7.22.3 CMIC Group Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  131. 7.22.4 CMIC Group Formulation Development CDMO Product Portfolio
  132. 7.22.5 CMIC Group Recent Developments
  133. 7.23 Hovione
  134. 7.23.1 Hovione Company Information
  135. 7.23.2 Hovione Business Overview
  136. 7.23.3 Hovione Formulation Development CDMO Revenue and Gross Margin (2021-2026)
  137. 7.23.4 Hovione Formulation Development CDMO Product Portfolio
  138. 7.23.5 Hovione Recent Developments
8 North America
  1. 8.1 North America Formulation Development CDMO Revenue (2021-2032)
  2. 8.2 North America Formulation Development CDMO Revenue by Type (2021-2032)
  3. 8.2.1 North America Formulation Development CDMO Revenue by Type (2021-2026)
  4. 8.2.2 North America Formulation Development CDMO Revenue by Type (2027-2032)
  5. 8.3 North America Formulation Development CDMO Revenue Share by Type (2021-2032)
  6. 8.4 North America Formulation Development CDMO Revenue by Application (2021-2032)
  7. 8.4.1 North America Formulation Development CDMO Revenue by Application (2021-2026)
  8. 8.4.2 North America Formulation Development CDMO Revenue by Application (2027-2032)
  9. 8.5 North America Formulation Development CDMO Revenue Share by Application (2021-2032)
  10. 8.6 North America Formulation Development CDMO Revenue by Country
  11. 8.6.1 North America Formulation Development CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Formulation Development CDMO Revenue by Country (2021-2026)
  13. 8.6.3 North America Formulation Development CDMO Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Formulation Development CDMO Revenue (2021-2032)
  2. 9.2 Europe Formulation Development CDMO Revenue by Type (2021-2032)
  3. 9.2.1 Europe Formulation Development CDMO Revenue by Type (2021-2026)
  4. 9.2.2 Europe Formulation Development CDMO Revenue by Type (2027-2032)
  5. 9.3 Europe Formulation Development CDMO Revenue Share by Type (2021-2032)
  6. 9.4 Europe Formulation Development CDMO Revenue by Application (2021-2032)
  7. 9.4.1 Europe Formulation Development CDMO Revenue by Application (2021-2026)
  8. 9.4.2 Europe Formulation Development CDMO Revenue by Application (2027-2032)
  9. 9.5 Europe Formulation Development CDMO Revenue Share by Application (2021-2032)
  10. 9.6 Europe Formulation Development CDMO Revenue by Country
  11. 9.6.1 Europe Formulation Development CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Formulation Development CDMO Revenue by Country (2021-2026)
  13. 9.6.3 Europe Formulation Development CDMO Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Formulation Development CDMO Revenue (2021-2032)
  2. 10.2 China Formulation Development CDMO Revenue by Type (2021-2032)
  3. 10.2.1 China Formulation Development CDMO Revenue by Type (2021-2026)
  4. 10.2.2 China Formulation Development CDMO Revenue by Type (2027-2032)
  5. 10.3 China Formulation Development CDMO Revenue Share by Type (2021-2032)
  6. 10.4 China Formulation Development CDMO Revenue by Application (2021-2032)
  7. 10.4.1 China Formulation Development CDMO Revenue by Application (2021-2026)
  8. 10.4.2 China Formulation Development CDMO Revenue by Application (2027-2032)
  9. 10.5 China Formulation Development CDMO Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Formulation Development CDMO Revenue (2021-2032)
  2. 11.2 Asia Formulation Development CDMO Revenue by Type (2021-2032)
  3. 11.2.1 Asia Formulation Development CDMO Revenue by Type (2021-2026)
  4. 11.2.2 Asia Formulation Development CDMO Revenue by Type (2027-2032)
  5. 11.3 Asia Formulation Development CDMO Revenue Share by Type (2021-2032)
  6. 11.4 Asia Formulation Development CDMO Revenue by Application (2021-2032)
  7. 11.4.1 Asia Formulation Development CDMO Revenue by Application (2021-2026)
  8. 11.4.2 Asia Formulation Development CDMO Revenue by Application (2027-2032)
  9. 11.5 Asia Formulation Development CDMO Revenue Share by Application (2021-2032)
  10. 11.6 Asia Formulation Development CDMO Revenue by Country
  11. 11.6.1 Asia Formulation Development CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Formulation Development CDMO Revenue by Country (2021-2026)
  13. 11.6.3 Asia Formulation Development CDMO Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Formulation Development CDMO Revenue (2021-2032)
  2. 12.2 SAMEA Formulation Development CDMO Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Formulation Development CDMO Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Formulation Development CDMO Revenue by Type (2027-2032)
  5. 12.3 SAMEA Formulation Development CDMO Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Formulation Development CDMO Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Formulation Development CDMO Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Formulation Development CDMO Revenue by Application (2027-2032)
  9. 12.5 SAMEA Formulation Development CDMO Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Formulation Development CDMO Revenue by Country
  11. 12.6.1 SAMEA Formulation Development CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Formulation Development CDMO Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Formulation Development CDMO Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst